Unlike Arg1 and STAT3 inhibitors, which generally aim to suppress specific immune-suppressive pathways [26, 49], IL-19 antibody therapy directly modulates the tumor microenvironment by addressing aberrant cytokine signaling. The gene discussed is STAT3; the disease is neoplasm.